
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
2
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
3
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
4
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
5





